Sanofi, Translate Bio Start Trial Evaluating Flu Vaccine
June 22 2021 - 6:36AM
Dow Jones News
By Chris Wack
Sanofi Pasteur, the vaccines global business unit of Sanofi SA,
and Translate Bio Inc. said they have begun a Phase 1 clinical
trial evaluating an mRNA-based investigational vaccine against
seasonal influenza.
The companies said the trial will evaluate the safety and
immunogenicity of a monovalent flu vaccine candidate coding for the
hemagglutinin protein of the A/H3N2 strain of the influenza
virus.
Flu seasons that are dominated by A/H3N2 strain circulation
activity tend to be more severe, especially among those considered
at-risk such as older adults and younger children.
Sanofi and Translate Bio have developed and will evaluate two
formulations of the vaccine in the Phase 1 influenza mRNA vaccine
clinical trial. The two formulations differ in the lipid
nanoparticle that contains the mRNA.
The trial follows successful preclinical research which
demonstrated promising safety and immunogenicity.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
June 22, 2021 06:24 ET (10:24 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sanofi (EU:SAN)
Historical Stock Chart
From Sep 2023 to Sep 2024